Table 2. Hazard ratio for each gene based on univariate Cox regression analysis.
| Gene | All stages (N = 95) | Stage I/II (N = 40) | Stage III (N = 13) | Stage IV (N = 42) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | P | 95% CI | HR | P | 95% CI | HR | P | 95% CI | HR | P | 95% CI | |
| ALX4 | 1.43 | 0.20 | (0.83-2.47) | 0.82 | 0.78 | (0.19-3.43) | 1.00 | - | - | 0.96 | 0.91 | (0.50-1.86) |
| APC | 0.99 | 0.97 | (0.58-1.70) | 0.88 | 0.76 | (0.38-2.01) | 0.40 | 0.21 | (0.09-1.69) | 1.34 | 0.51 | (0.56-3.19) |
| BMP3 | 1.41 | 0.13 | (0.91-2.18) | 0.80 | 0.59 | (0.37-1.77) | 0.71 | 0.58 | (0.21-2.41) | 3.21 | 0.00 | (1.58-6.53) |
| BNC1 | 2.10 | 0.00 | (1.36-3.25) | 1.26 | 0.61 | (0.52-3.06) | 1.93 | 0.30 | (0.55-6.75) | 1.69 | 0.11 | (0.88-3.21) |
| BRCA1 | 0.76 | 0.44 | (0.38-1.52) | 0.88 | 0.82 | (0.31-2.52) | 0.00 | 1.00 | - | 2.42 | 0.16 | (0.70-8.34) |
| CDKN2B | 0.80 | 0.49 | (0.42-1.51) | 0.79 | 0.59 | (0.33-1.90) | 1.18 | 0.84 | (0.25-5.63) | 1.82 | 0.33 | (0.55-6.03) |
| CHFR | 0.38 | 0.34 | (0.05-2.76) | 0.53 | 0.53 | (0.07-3.90) | 1.00 | - | - | 1.00 | - | - |
| ESR1 | 1.21 | 0.45 | (0.74-1.99) | 0.89 | 0.75 | (0.44-1.82) | 0.68 | 0.64 | (0.14-3.40) | 1.27 | 0.57 | (0.56-2.89) |
| EYA2 | 1.41 | 0.26 | (0.78-2.55) | 1.93 | 0.15 | (0.79-4.71) | 0.54 | 0.57 | (0.07-4.37) | 1.31 | 0.54 | (0.55-3.16) |
| GSTP1 | 6.91 | 0.00 | (2.08-22.96) | 1.00 | - | - | * | 1.00 | (0.00- --) | 2.33 | 0.26 | (0.54-9.99) |
| HIC1 | 1.37 | 0.27 | (0.78-2.39) | 1.49 | 0.46 | (0.51-4.34) | 1.00 | - | - | 0.92 | 0.82 | (0.45-1.88) |
| MEST1v2 | 1.45 | 0.16 | (0.86-2.45) | 1.97 | 0.13 | (0.81-4.79) | 1.88 | 0.36 | (0.49-7.22) | 1.21 | 0.63 | (0.56-2.64) |
| MGMT | 2.21 | 0.09 | (0.88-5.54) | 3.02 | 0.29 | (0.39-23.38) | 0.71 | 0.75 | (0.09-5.71) | 3.45 | 0.06 | (0.96-12.44) |
| MLH1 | 1.85 | 0.04 | (1.03-3.32) | 1.54 | 0.49 | (0.46-5.18) | 0.95 | 0.94 | (0.24-3.70) | 1.79 | 0.15 | (0.81-3.96) |
| NPTX2 | 1.05 | 0.85 | (0.65-1.68) | 1.12 | 0.75 | (0.55-2.29) | 0.70 | 0.55 | (0.22-2.26) | 0.62 | 0.26 | (0.27-1.42) |
| NEUROG1 | 1.41 | 0.32 | (0.72-2.74) | 2.51 | 0.22 | (0.57-11.00) | 0.38 | 0.37 | (0.05-3.13) | 0.85 | 0.70 | (0.38-1.93) |
| RARB | 1.07 | 0.73 | (0.71-1.62) | 1.03 | 0.93 | (0.53-1.99) | 1.64 | 0.42 | (0.49-5.43) | 0.98 | 0.95 | (0.53-1.82) |
| RASSF1A | 1.30 | 0.22 | (0.86-1.97) | 1.35 | 0.39 | (0.68-2.68) | 1.08 | 0.90 | (0.34-3.49) | 1.33 | 0.38 | (0.70-2.51) |
| SFRP1 | 2.11 | 0.00 | (1.38-3.23) | 1.60 | 0.17 | (0.82-3.13) | 3.50 | 0.08 | (0.86-14.22) | 4.57 | 0.00 | (2.02-10.34) |
| SFRP2 | 0.73 | 0.17 | (0.46-1.14) | 0.31 | 0.01 | (0.14-0.71) | 2.47 | 0.28 | (0.48-12.86) | 1.08 | 0.81 | (0.58-2.02) |
| SEPT9v2 | 2.37 | 0.00 | (1.32-4.27) | 3.37 | 0.25 | (0.43-26.37) | 1.00 | - | - | 1.22 | 0.55 | (0.63-2.38) |
| SST | 1.63 | 0.03 | (1.06-2.51) | 1.15 | 0.67 | (0.60-2.23) | 2.44 | 0.15 | (0.72-8.33) | 1.67 | 0.23 | (0.73-3.80) |
| TFPI2 | 2.22 | 0.00 | (1.34-3.68) | 1.39 | 0.50 | (0.53-3.63) | 5.48 | 0.17 | (0.50-60.52) | 2.59 | 0.01 | (1.25-5.39) |
| TAC1 | 1.44 | 0.09 | (0.95-2.20) | 1.06 | 0.87 | (0.55-2.04) | 1.28 | 0.69 | (0.37-4.45) | 1.69 | 0.16 | (0.81-3.52) |
| VIM | 1.55 | 0.46 | (0.49-4.94) | 1.20 | 0.86 | (0.16-8.94) | 1.00 | - | - | 1.89 | 0.39 | (0.45-8.00) |
| WNT5A | 2.32 | 0.03 | (1.09-4.94) | 3.02 | 0.29 | (0.39-23.38) | 7.05 | 0.05 | (0.97-51.19) | 1.05 | 0.91 | (0.41-2.72) |
| CDKN2A | 1.71 | 0.22 | (0.73-3.97) | 9.24 | 0.05 | (1.03-82.68) | 1.00 | - | - | 0.76 | 0.56 | (0.29-1.95) |
| PENK | 2.03 | 0.33 | (0.49-8.40) | 1.00 | - | - | 1.00 | - | - | 0.96 | 0.95 | (0.23-4.02) |
Variable analyzed by simple Cox regression analysis.
Bold marks the genes with a statistically significant HR.
HR: Hazard ratio.
CI: Confidence interval.
Note: Stage is in accordance with The American Joint Committee on Cancer stage classification.
*One patients with stage III disease had hypermethylation of GSTP1. This patient died only eight days after the diagnosis, resulting in a HR of 19.32x10^16 (p-value = 1) for GSTP1 hypermethylation in stage III disease.